ab4469 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab4469 は 18 報の論文で使用されています。

  • Labade AS  et al. HOXA repression is mediated by nucleoporin Nup93 assisted by its interactors Nup188 and Nup205. Epigenetics Chromatin 9:54 (2016). WB ; Human . PubMed: 27980680
  • Englert NA  et al. Epigenetic modification of histone 3 lysine 27: mediator subunit MED25 is required for the dissociation of polycomb repressive complex 2 from the promoter of cytochrome P450 2C9. J Biol Chem 290:2264-78 (2015). PubMed: 25391650
  • Mitic T  et al. EZH2 modulates angiogenesis in vitro and in a mouse model of limb ischemia. Mol Ther 23:32-42 (2015). PubMed: 25189741
  • Wan J  et al. PCAF-primed EZH2 acetylation regulates its stability and promotes lung adenocarcinoma progression. Nucleic Acids Res 43:3591-604 (2015). Human . PubMed: 25800736
  • Gonzalez ME  et al. EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc Natl Acad Sci U S A 111:3098-103 (2014). WB ; Human . PubMed: 24516139
  • Lee W  et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46:1227-32 (2014). WB ; Human . PubMed: 25240281
  • Moore HM  et al. EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis. Breast Cancer Res Treat 138:741-52 (2013). Human . PubMed: 23539298
  • Bengani H  et al. Identification and Validation of a Putative Polycomb Responsive Element in the Human Genome. PLoS One 8:e67217 (2013). PubMed: 23805300
  • Kim W  et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol 9:643-50 (2013). PubMed: 23974116
  • Wang C  et al. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res 72:315-24 (2012). WB, ChIP . PubMed: 22068036
  • Su L  et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell 21:333-47 (2012). PubMed: 22439931
  • Abdel-Wahab O  et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22:180-93 (2012). PubMed: 22897849
  • Yap DB  et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117:2451-9 (2011). WB ; Human . PubMed: 21190999
  • Borbone E  et al. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J Clin Endocrinol Metab 96:1029-38 (2011). PubMed: 21289264
  • Choudhury SR  et al. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis 32:1525-32 (2011). PubMed: 21798853
  • Philipp S  et al. The Polycomb group protein EED couples TNF receptor 1 to neutral sphingomyelinase. Proc Natl Acad Sci U S A 107:1112-7 (2010). WB, ICC/IF ; Human . PubMed: 20080539
  • Maenner S  et al. 2-D structure of the A region of Xist RNA and its implication for PRC2 association. PLoS Biol 8:e1000276 (2010). WB . PubMed: 20052282
  • Ross PJ  et al. Polycomb gene expression and histone H3 lysine 27 trimethylation changes during bovine preimplantation development. Reproduction 136:777-85 (2008). WB, IHC-FoFr ; Cow . PubMed: 18784248